author_facet Frère, Pascale
Baron, Frédéric
Bonnet, Christoffe
Hafraoui, Kaoutar
Pereira, Maguy
Willems, Evelyne
Fillet, Georges
Beguin, Yves
Frère, Pascale
Baron, Frédéric
Bonnet, Christoffe
Hafraoui, Kaoutar
Pereira, Maguy
Willems, Evelyne
Fillet, Georges
Beguin, Yves
author Frère, Pascale
Baron, Frédéric
Bonnet, Christoffe
Hafraoui, Kaoutar
Pereira, Maguy
Willems, Evelyne
Fillet, Georges
Beguin, Yves
spellingShingle Frère, Pascale
Baron, Frédéric
Bonnet, Christoffe
Hafraoui, Kaoutar
Pereira, Maguy
Willems, Evelyne
Fillet, Georges
Beguin, Yves
Blood
Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
Cell Biology
Hematology
Immunology
Biochemistry
author_sort frère, pascale
spelling Frère, Pascale Baron, Frédéric Bonnet, Christoffe Hafraoui, Kaoutar Pereira, Maguy Willems, Evelyne Fillet, Georges Beguin, Yves 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v104.11.5086.5086 <jats:title>Abstract</jats:title> <jats:p>Hematopoietic stem cell transplantation with a non-myeloablative conditioning (NMSCT) could theoretically be associated with a reduced risk of infection because it causes less mucosal damage or severe neutropenia compared to standard myeloablative allogeneic transplantation. Previous studies have sometimes indicated a reduced incidence of infection after NMSCT but other reports have not. We analyzed the incidence and risk factors (Cox model) of infection in 62 patients (16 F and 46 M, aged 54±11 yrs) undergoing NMSCT with a conditioning regimen of low-dose TBI±fludarabine and immunosuppression with CsA+MMF (Seattle protocol). We compared them to 119 recipients (72 peripheral blood (PBSCT) and 47 bone marrow (BMT) transplants) of a conventional HCT. The proportion of NMSCT patients with repeated infections (at least 1, 2, 3 or 4 infections) was significantly lower than in the 2 other groups, but the difference was confined to the first 30 days post-transplant (34% vs 89% and 74%, p&lt;0.001). In NMSCT recipients, donor other than sibling (p&lt;0.0001), older age (p=0.0024), a diagnosis of MDS (p=0.0123), early disease (p=0.0233) and male gender (p=0.0441) were significant risk factors. The incidence of bacteremia was lower (55% vs 70% and 66% at 1 yr, p=0.0264), but the total number of bacteremic episodes (0.9, 1.2 and 1.0 per patient) did not differ in the NMSCT compared to the PBSCT and BMT groups. However, in the first 30 days post-transplant, 4–6 times fewer episodes were encountered in the NMSCT group (p&lt;0.0001). In the NMSCT group, donor other than sibling (p&lt;0.0001), older age (p=0.0126), a diagnosis of leukemia (p=0.0099) and conditioning without fludarabine (p=0.0022), but not neutropenia, were significant risk factors. The incidence of infections other than bacteremia was quite comparable in the 3 groups, but with a significant delay in the NMSCT group (p=0.0002) in which only corticosteroid usage was associated with an increased risk (p=0.0066). The vast majority of infections were bacterial (less frequent in the NMSCT group in the first 30 days), but the rates of fungal or VZV infections were similar in the 3 groups. No case of CMV reactivation or disease occurred among the low risk (donor and recipient seronegative), very few in the intermediate risk (donor alone seropositive), but many in the high risk category (recipient seropositive) and similarly so in the 3 groups. Among NMSCT patients, the risk of CMV infection increased with high risk category (p&lt;0.0001), older age (p=0.0002), donor other than sibling (p=0.0003) and a diagnosis of lymphoma (p=0.0035). Infection was the primary cause of death in 10% or less of the patients, but it contributed to death in 24%, 41% and 27% of the NMSCT, PBSCT and BMT patients, respectively (NS). We conclude that the risk of infection after NMSCT is significantly smaller than after standard allogeneic transplants within 30 days posttransplant, but very similar thereafter.</jats:p> Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen. Blood
doi_str_mv 10.1182/blood.v104.11.5086.5086
facet_avail Online
Free
finc_class_facet Biologie
Medizin
Chemie und Pharmazie
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA0LjExLjUwODYuNTA4Ng
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA0LjExLjUwODYuNTA4Ng
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint American Society of Hematology, 2004
imprint_str_mv American Society of Hematology, 2004
issn 0006-4971
1528-0020
issn_str_mv 0006-4971
1528-0020
language English
mega_collection American Society of Hematology (CrossRef)
match_str frere2004infectionsafterallogeneichematopoieticstemcelltransplantationwithanonmyeloablativeconditioningregimen
publishDateSort 2004
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood
source_id 49
title Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_unstemmed Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_full Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_fullStr Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_full_unstemmed Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_short Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_sort infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.
topic Cell Biology
Hematology
Immunology
Biochemistry
url http://dx.doi.org/10.1182/blood.v104.11.5086.5086
publishDate 2004
physical 5086-5086
description <jats:title>Abstract</jats:title> <jats:p>Hematopoietic stem cell transplantation with a non-myeloablative conditioning (NMSCT) could theoretically be associated with a reduced risk of infection because it causes less mucosal damage or severe neutropenia compared to standard myeloablative allogeneic transplantation. Previous studies have sometimes indicated a reduced incidence of infection after NMSCT but other reports have not. We analyzed the incidence and risk factors (Cox model) of infection in 62 patients (16 F and 46 M, aged 54±11 yrs) undergoing NMSCT with a conditioning regimen of low-dose TBI±fludarabine and immunosuppression with CsA+MMF (Seattle protocol). We compared them to 119 recipients (72 peripheral blood (PBSCT) and 47 bone marrow (BMT) transplants) of a conventional HCT. The proportion of NMSCT patients with repeated infections (at least 1, 2, 3 or 4 infections) was significantly lower than in the 2 other groups, but the difference was confined to the first 30 days post-transplant (34% vs 89% and 74%, p&lt;0.001). In NMSCT recipients, donor other than sibling (p&lt;0.0001), older age (p=0.0024), a diagnosis of MDS (p=0.0123), early disease (p=0.0233) and male gender (p=0.0441) were significant risk factors. The incidence of bacteremia was lower (55% vs 70% and 66% at 1 yr, p=0.0264), but the total number of bacteremic episodes (0.9, 1.2 and 1.0 per patient) did not differ in the NMSCT compared to the PBSCT and BMT groups. However, in the first 30 days post-transplant, 4–6 times fewer episodes were encountered in the NMSCT group (p&lt;0.0001). In the NMSCT group, donor other than sibling (p&lt;0.0001), older age (p=0.0126), a diagnosis of leukemia (p=0.0099) and conditioning without fludarabine (p=0.0022), but not neutropenia, were significant risk factors. The incidence of infections other than bacteremia was quite comparable in the 3 groups, but with a significant delay in the NMSCT group (p=0.0002) in which only corticosteroid usage was associated with an increased risk (p=0.0066). The vast majority of infections were bacterial (less frequent in the NMSCT group in the first 30 days), but the rates of fungal or VZV infections were similar in the 3 groups. No case of CMV reactivation or disease occurred among the low risk (donor and recipient seronegative), very few in the intermediate risk (donor alone seropositive), but many in the high risk category (recipient seropositive) and similarly so in the 3 groups. Among NMSCT patients, the risk of CMV infection increased with high risk category (p&lt;0.0001), older age (p=0.0002), donor other than sibling (p=0.0003) and a diagnosis of lymphoma (p=0.0035). Infection was the primary cause of death in 10% or less of the patients, but it contributed to death in 24%, 41% and 27% of the NMSCT, PBSCT and BMT patients, respectively (NS). We conclude that the risk of infection after NMSCT is significantly smaller than after standard allogeneic transplants within 30 days posttransplant, but very similar thereafter.</jats:p>
container_issue 11
container_start_page 5086
container_title Blood
container_volume 104
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792321128527560714
geogr_code not assigned
last_indexed 2024-03-01T10:57:03.839Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Infections+after+Allogeneic+Hematopoietic+Stem+Cell+Transplantation+with+a+Nonmyeloablative+Conditioning+Regimen.&rft.date=2004-11-16&genre=article&issn=1528-0020&volume=104&issue=11&spage=5086&epage=5086&pages=5086-5086&jtitle=Blood&atitle=Infections+after+Allogeneic+Hematopoietic+Stem+Cell+Transplantation+with+a+Nonmyeloablative+Conditioning+Regimen.&aulast=Beguin&aufirst=Yves&rft_id=info%3Adoi%2F10.1182%2Fblood.v104.11.5086.5086&rft.language%5B0%5D=eng
SOLR
_version_ 1792321128527560714
author Frère, Pascale, Baron, Frédéric, Bonnet, Christoffe, Hafraoui, Kaoutar, Pereira, Maguy, Willems, Evelyne, Fillet, Georges, Beguin, Yves
author_facet Frère, Pascale, Baron, Frédéric, Bonnet, Christoffe, Hafraoui, Kaoutar, Pereira, Maguy, Willems, Evelyne, Fillet, Georges, Beguin, Yves, Frère, Pascale, Baron, Frédéric, Bonnet, Christoffe, Hafraoui, Kaoutar, Pereira, Maguy, Willems, Evelyne, Fillet, Georges, Beguin, Yves
author_sort frère, pascale
container_issue 11
container_start_page 5086
container_title Blood
container_volume 104
description <jats:title>Abstract</jats:title> <jats:p>Hematopoietic stem cell transplantation with a non-myeloablative conditioning (NMSCT) could theoretically be associated with a reduced risk of infection because it causes less mucosal damage or severe neutropenia compared to standard myeloablative allogeneic transplantation. Previous studies have sometimes indicated a reduced incidence of infection after NMSCT but other reports have not. We analyzed the incidence and risk factors (Cox model) of infection in 62 patients (16 F and 46 M, aged 54±11 yrs) undergoing NMSCT with a conditioning regimen of low-dose TBI±fludarabine and immunosuppression with CsA+MMF (Seattle protocol). We compared them to 119 recipients (72 peripheral blood (PBSCT) and 47 bone marrow (BMT) transplants) of a conventional HCT. The proportion of NMSCT patients with repeated infections (at least 1, 2, 3 or 4 infections) was significantly lower than in the 2 other groups, but the difference was confined to the first 30 days post-transplant (34% vs 89% and 74%, p&lt;0.001). In NMSCT recipients, donor other than sibling (p&lt;0.0001), older age (p=0.0024), a diagnosis of MDS (p=0.0123), early disease (p=0.0233) and male gender (p=0.0441) were significant risk factors. The incidence of bacteremia was lower (55% vs 70% and 66% at 1 yr, p=0.0264), but the total number of bacteremic episodes (0.9, 1.2 and 1.0 per patient) did not differ in the NMSCT compared to the PBSCT and BMT groups. However, in the first 30 days post-transplant, 4–6 times fewer episodes were encountered in the NMSCT group (p&lt;0.0001). In the NMSCT group, donor other than sibling (p&lt;0.0001), older age (p=0.0126), a diagnosis of leukemia (p=0.0099) and conditioning without fludarabine (p=0.0022), but not neutropenia, were significant risk factors. The incidence of infections other than bacteremia was quite comparable in the 3 groups, but with a significant delay in the NMSCT group (p=0.0002) in which only corticosteroid usage was associated with an increased risk (p=0.0066). The vast majority of infections were bacterial (less frequent in the NMSCT group in the first 30 days), but the rates of fungal or VZV infections were similar in the 3 groups. No case of CMV reactivation or disease occurred among the low risk (donor and recipient seronegative), very few in the intermediate risk (donor alone seropositive), but many in the high risk category (recipient seropositive) and similarly so in the 3 groups. Among NMSCT patients, the risk of CMV infection increased with high risk category (p&lt;0.0001), older age (p=0.0002), donor other than sibling (p=0.0003) and a diagnosis of lymphoma (p=0.0035). Infection was the primary cause of death in 10% or less of the patients, but it contributed to death in 24%, 41% and 27% of the NMSCT, PBSCT and BMT patients, respectively (NS). We conclude that the risk of infection after NMSCT is significantly smaller than after standard allogeneic transplants within 30 days posttransplant, but very similar thereafter.</jats:p>
doi_str_mv 10.1182/blood.v104.11.5086.5086
facet_avail Online, Free
finc_class_facet Biologie, Medizin, Chemie und Pharmazie
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA0LjExLjUwODYuNTA4Ng
imprint American Society of Hematology, 2004
imprint_str_mv American Society of Hematology, 2004
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 0006-4971, 1528-0020
issn_str_mv 0006-4971, 1528-0020
language English
last_indexed 2024-03-01T10:57:03.839Z
match_str frere2004infectionsafterallogeneichematopoieticstemcelltransplantationwithanonmyeloablativeconditioningregimen
mega_collection American Society of Hematology (CrossRef)
physical 5086-5086
publishDate 2004
publishDateSort 2004
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood
source_id 49
spelling Frère, Pascale Baron, Frédéric Bonnet, Christoffe Hafraoui, Kaoutar Pereira, Maguy Willems, Evelyne Fillet, Georges Beguin, Yves 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v104.11.5086.5086 <jats:title>Abstract</jats:title> <jats:p>Hematopoietic stem cell transplantation with a non-myeloablative conditioning (NMSCT) could theoretically be associated with a reduced risk of infection because it causes less mucosal damage or severe neutropenia compared to standard myeloablative allogeneic transplantation. Previous studies have sometimes indicated a reduced incidence of infection after NMSCT but other reports have not. We analyzed the incidence and risk factors (Cox model) of infection in 62 patients (16 F and 46 M, aged 54±11 yrs) undergoing NMSCT with a conditioning regimen of low-dose TBI±fludarabine and immunosuppression with CsA+MMF (Seattle protocol). We compared them to 119 recipients (72 peripheral blood (PBSCT) and 47 bone marrow (BMT) transplants) of a conventional HCT. The proportion of NMSCT patients with repeated infections (at least 1, 2, 3 or 4 infections) was significantly lower than in the 2 other groups, but the difference was confined to the first 30 days post-transplant (34% vs 89% and 74%, p&lt;0.001). In NMSCT recipients, donor other than sibling (p&lt;0.0001), older age (p=0.0024), a diagnosis of MDS (p=0.0123), early disease (p=0.0233) and male gender (p=0.0441) were significant risk factors. The incidence of bacteremia was lower (55% vs 70% and 66% at 1 yr, p=0.0264), but the total number of bacteremic episodes (0.9, 1.2 and 1.0 per patient) did not differ in the NMSCT compared to the PBSCT and BMT groups. However, in the first 30 days post-transplant, 4–6 times fewer episodes were encountered in the NMSCT group (p&lt;0.0001). In the NMSCT group, donor other than sibling (p&lt;0.0001), older age (p=0.0126), a diagnosis of leukemia (p=0.0099) and conditioning without fludarabine (p=0.0022), but not neutropenia, were significant risk factors. The incidence of infections other than bacteremia was quite comparable in the 3 groups, but with a significant delay in the NMSCT group (p=0.0002) in which only corticosteroid usage was associated with an increased risk (p=0.0066). The vast majority of infections were bacterial (less frequent in the NMSCT group in the first 30 days), but the rates of fungal or VZV infections were similar in the 3 groups. No case of CMV reactivation or disease occurred among the low risk (donor and recipient seronegative), very few in the intermediate risk (donor alone seropositive), but many in the high risk category (recipient seropositive) and similarly so in the 3 groups. Among NMSCT patients, the risk of CMV infection increased with high risk category (p&lt;0.0001), older age (p=0.0002), donor other than sibling (p=0.0003) and a diagnosis of lymphoma (p=0.0035). Infection was the primary cause of death in 10% or less of the patients, but it contributed to death in 24%, 41% and 27% of the NMSCT, PBSCT and BMT patients, respectively (NS). We conclude that the risk of infection after NMSCT is significantly smaller than after standard allogeneic transplants within 30 days posttransplant, but very similar thereafter.</jats:p> Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen. Blood
spellingShingle Frère, Pascale, Baron, Frédéric, Bonnet, Christoffe, Hafraoui, Kaoutar, Pereira, Maguy, Willems, Evelyne, Fillet, Georges, Beguin, Yves, Blood, Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen., Cell Biology, Hematology, Immunology, Biochemistry
title Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_full Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_fullStr Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_full_unstemmed Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_short Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
title_sort infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.
title_unstemmed Infections after Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen.
topic Cell Biology, Hematology, Immunology, Biochemistry
url http://dx.doi.org/10.1182/blood.v104.11.5086.5086